Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive prolonged-release ketamine with new antidepressant in major depressive disorder
2025-524841-28-00Phase 2Completed
- Sponsor
- Region Skåne
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Region Skåne. Primary endpoint: Change in MADRS total score at day 8. Started Mar 2026; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-524841-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524841-28-00.